Design Considerations for Devices Intended for Home Use Guidance for Industry and Food and Drug Administration Staff Document issued on August - Description

The draft of this document was issued on December 13 2012 For questions about this document regarding CDRHregulated devices contact Mary Brady at 3017966089 or by email at marybradyfdahhsgov or contact the Office of the Center Director at 30179659 ID: 12988 Download Pdf

Similar presentations

Custom Device Exemption Guidance for Industry and Food and Drug Administration Staff Document issued on September The draft of this d ocument was issued on January
Custom Device Exemption Guidance for Industry and Food and Drug Administration Staff Document issued on September The draft of this d ocument was issued on January

See additional PRA statement in Sec tion VIII of this guidance RU57347TXHVWLRQV57347UHJDUGLQJ57347WKLV57347GRFXPHQW5735957347FRQWDFW57347WKH57347LYLVLRQ57347RI573473UHPDUNHW57347DQG57347DEHOLQJ RPSOLDQFH57347573553 DW57347WKH57347HQWHU57347IRU57347H

Management Review Management
Management Review Management

Representative: First Last. Date: . February . 4. , 2015. Location: . Misc. . Conference Room. Management Review Agenda. Roll Call of Attendees (5.6.1). Suitability of Quality Policy (5.3e). Status of Quality Objectives (.

Draft Guidance for Industry and Food and Drug Administration Staff ...
Draft Guidance for Industry and Food and Drug Administration Staff ...

4 9 DRAFT GUIDANCE ) or the Office of Communication, Outreach, and Development (CBER) at 8004709 or 240 27 U.S. Department of Health and Human ServicesFood and Drug Administration Center for Device

Guidance for Industry Interim Product Reporting for Human Drug Compounding Outsourcing Facilities nder Section B of the Federal Food Drug and Cosmetic Act DRAFT GUIDANCE This guidance document is bei
Guidance for Industry Interim Product Reporting for Human Drug Compounding Outsourcing Facilities nder Section B of the Federal Food Drug and Cosmetic Act DRAFT GUIDANCE This guidance document is bei

omments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments to httpwwwregulationsgov Subm

Benefit Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications k with Different Technological Characteristics Draft Guidance for Industry and Food and Drug Admin
Benefit Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications k with Different Technological Characteristics Draft Guidance for Industry and Food and Drug Admin

Document issued on July 15 2014 You should submit comments and suggestions regarding this draft document within 90 days of publication in the Federal Register of the no tice announcing the availability of the draft guidance Submit comments to the Di

Guidance for Industry Considerations for the Design of Early Phase Clinical Trials of Cellular and Gene Therapy Products DRAFT GUIDANCE This guidance document is for comment purposes only
Guidance for Industry Considerations for the Design of Early Phase Clinical Trials of Cellular and Gene Therapy Products DRAFT GUIDANCE This guidance document is for comment purposes only

Submit one set of either electronic or written comments on this draft guidance by the date provided in the Federal Register notice announcing the availability of the draft guidance Submit electronic comments to httpwwwregulationsgov Submit written

Guidance for Industry Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors DRAFT GUIDANCE This guidance document is being di stributed for comment pur
Guidance for Industry Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors DRAFT GUIDANCE This guidance document is being di stributed for comment pur

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments to httpwwwregulationsgov Sub

Guidance for Industry and FDA Staff Commercially Distributed Analyte Specific Reagents ASRs Frequently Asked Questions Document issued on September The draft of this guidance docume nt was released
Guidance for Industry and FDA Staff Commercially Distributed Analyte Specific Reagents ASRs Frequently Asked Questions Document issued on September The draft of this guidance docume nt was released

US Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Office of In Vitro Diagnostic Device Evaluation and Safety Center for Biologic Evaluation and Research brPage 2br Contains NonBinding

Guidance for Industry Naming of Drug Products Containing Salt Drug Substances DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only
Guidance for Industry Naming of Drug Products Containing Salt Drug Substances DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments to httpwwwregulationsgov Sub

Food and Drug Administration Report on Good Guidance Practices Improving Efficiency and Transparency Completed September Issued December Table of Contents INTRODUCTION
Food and Drug Administration Report on Good Guidance Practices Improving Efficiency and Transparency Completed September Issued December Table of Contents INTRODUCTION

1 CHAPTER 1 INITIATING GUIDANCE 5 I UMMARY OF URRENT UIDANCE NITIATION RACTICES 5 A Current Stakeholder Input Prior to Guidance Development 5 B Current DecisionMak ing Processes For In itiating Guid ance 6 II ECOMMENDATIONS 6 CHAPTER 2 PRIORITIZI

171K - views

Design Considerations for Devices Intended for Home Use Guidance for Industry and Food and Drug Administration Staff Document issued on August

Published byalida-meadow

The draft of this document was issued on December 13 2012 For questions about this document regarding CDRHregulated devices contact Mary Brady at 3017966089 or by email at marybradyfdahhsgov or contact the Office of the Center Director at 30179659

Tags : The draft this
Embed :
Pdf Download Link

Download Pdf - The PPT/PDF document " Design Considerations for Devices Inten..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Design Considerations for Devices Intended for Home Use Guidance for Industry and Food and Drug Administration Staff Document issued on August






Presentation on theme: " Design Considerations for Devices Intended for Home Use Guidance for Industry and Food and Drug Administration Staff Document issued on August "— Presentation transcript: